Maegim한국어

삼성제약

001360KOSPISector: Pharma & Biotech
₩1,300▲ 2.20%Market cap ₩122.4BAs of Jul 21, 2026 close · updated once daily
B
Grade B53.8 ptsTop 46% of 2,523 stocks
Financial strength
51.8
Growth momentum
32.4
Price attractiveness
71.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

51.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
38.3%
✓ Above median · Top 34.8% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
92.1%
✗ Below median · Top 78.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-39.2%
✗ Below median · Top 65.6% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
9.5%
✓ Above median · Top 13.6% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

32.4
How much did revenue grow in a year?
Revenue growth (YoY)
4.0%
✗ Below median · Top 58.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-3.8%
✗ Below median · Top 76.1% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-21.8%
✗ Below median · Top 73% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-29.4%
✗ Below median · Top 62.6% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

71.5
Is the price expensive relative to earnings?
P/E (price-to-earnings)
10.6x
✓ Above median · Top 15.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.01x
✓ Above median · Top 41.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15